Clinical trial
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects…
NCT00038532 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00038532 |
|---|---|
| Title | Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART |
| Official title | An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Amprenavir/ritonavir, Saquinavir/ritonavir, Efavirenz |
| Enrollment | 24 |
| Start date | Apr 1, 2001 |
| First posted | Jun 3, 2002 |
| Last update posted | Apr 1, 2008 |
| Countries | Argentina, Brazil, Canada, France, Germany, Italy, Poland, Puerto Rico, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: